Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Company Deals

Regeneron Partners with Parabilis Medicines on $2.2B Helicon Peptide Platform Deal Targeting “Undruggable” Proteins

Fineline Cube May 19, 2026
Company Deals

Shimai Pharmaceutical Files Hong Kong IPO Prospectus with Advanced T-Cell Engager Pipeline

Fineline Cube May 19, 2026
Company Deals

Youcare Pharmaceutical Commits $147M to Build Nucleic Acid Drug Manufacturing Base in Hangzhou Biopharma Town

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri

Fineline Cube May 19, 2026
Company Drug

Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease

Fineline Cube May 19, 2026
Company Drug

SCG Cell Therapy Presents Phase I Data for HBV-Specific TCR-T Therapy SCG101 at AASLD 2024

Fineline Cube Nov 26, 2024

SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has announced...

Company Drug

Shenzhen Kangtai Begins Phase I Clinical Trial for 20-Valent Pneumococcal Vaccine

Fineline Cube Nov 26, 2024

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the enrollment of the...

Company Drug

Sichuan Kelun-Biotech Receives NMPA Clearance for SKB501 Clinical Trial in Solid Tumors

Fineline Cube Nov 26, 2024

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that it has received clearance from...

Company Drug

Lepu Medical Technology Gains NMPA Approval for Obesity and Diabetes Treatments MWN109 and MWN105

Fineline Cube Nov 26, 2024

China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease...

Company Deals

3SBio Inc. Secures Licensing Deal with Sunshine Lake Pharma for Clifutinib Commercialization

Fineline Cube Nov 26, 2024

China-based 3SBio Inc. (HKG: 1530) has announced a licensing deal with fellow Chinese firm Sunshine...

Company Drug

Merck’s Winrevair Shows Positive Results in Phase III ZENITH Study for PAH

Fineline Cube Nov 26, 2024

US-based pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) has announced favorable interim analysis results...

Company Deals

Hubei Guangji Pharmaceutical Expands Ex-Hospital Market Presence with New Partnerships

Fineline Cube Nov 26, 2024

China-based Hubei Guangji Pharmaceutical Co., Ltd. (SHE: 000952) is poised to establish a strong presence...

Company Drug

GeneQuantum Healthcare’s GQ1011 (AMB302) Receives FDA Approval for Clinical Study

Fineline Cube Nov 26, 2024

China-based GeneQuantum Healthcare, a leading developer of antibody drug conjugates (ADCs), has announced that it...

Company Deals

E-nitiate Biopharmaceuticals Strikes Licensing Deal with Joincare for QY101 Inhaler Rights

Fineline Cube Nov 26, 2024

China-based E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd, a joint venture between VivaVision Biotech and Betta Pharmaceuticals...

Company Deals

Luye Pharma’s Subsidiary Boan Biotech Strikes Licensing Deal for Biosimilars in Brazil

Fineline Cube Nov 25, 2024

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),...

Company Deals

Dizal Pharmaceutical Co., Ltd Scales Back Private Placement Fundraising to USD 255.1 Million

Fineline Cube Nov 25, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced revisions to its private placement plan,...

Company

Danish Pharma H. Lundbeck A/S Sees Strong Q3 and Q1-Q3 2024 Financial Results

Fineline Cube Nov 25, 2024

Denmark-based pharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has revealed its financial results for the...

Policy / Regulatory

National Allied Procurement Office Announces Round 10 VBP Tender Program with New Rules

Fineline Cube Nov 25, 2024

The National Allied Procurement Office has released a notification regarding Round 10 of the national...

Policy / Regulatory

Jiangsu Chia Tai Fenghai’s ALS Treatment FHND1002 Selected for CDE’s Patient-Centered Care Plan

Fineline Cube Nov 25, 2024

China’s Center for Drug Evaluation (CDE) has announced its intention to include Jiangsu Chia Tai...

Company Medical Device

Acotec Scientific Holdings Receives NMPA Approval for Thrombus Aspiration Catheter Support Tube

Fineline Cube Nov 25, 2024

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...

Company Drug

Henlius Biotech Initiates Phase III Study for HLX22 in Gastric Cancer Treatment

Fineline Cube Nov 25, 2024

Shanghai Henlius Biotech Co., Ltd (HKG: 2696) has announced the dosing of the first patient...

Policy / Regulatory

China’s NHC Sets Sights on Enhancing Grassroots Drug Management and Access

Fineline Cube Nov 25, 2024

The National Health Commission (NHC) has issued a set of opinions designed to accelerate the...

Company Drug

MicroPort Scientific Corp.’s BonaFire Receives NMPA Approval as First Whole-Body MRI Safety Pacing Electrode Lead

Fineline Cube Nov 25, 2024

Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced that it has received...

Company Drug

Base Therapeutics’ NK510 Receives US FDA Clearance for Advanced Solid Tumor Studies

Fineline Cube Nov 25, 2024

Shanghai-based cell therapy specialist Base Therapeutics has achieved clearance from the US Food and Drug...

Company Deals

Merck KGaA Partners with NTU Singapore to Drive Digital Transformation with Trust Technology

Fineline Cube Nov 25, 2024

Merck KGaA (NYSE: MRK) has entered into a Memorandum of Understanding with the Digital Trust...

Posts pagination

1 … 262 263 264 … 668

Recent updates

  • Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri
  • GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams
  • Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B
  • Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC
  • Lundbeck’s Asedebart Receives Japanese Orphan Drug Designation for Congenital Adrenal Hyperplasia and Cushing’s Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bio-Thera Solutions Secures FDA Approval for Golimumab Biosimilars Immgolis and Immgolis Intri

Company

GSK Restructures China Vaccine Business with Dedicated Shingrix and Engerix-B Teams

Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.